Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors
CONCLUSIONS: The diversity of pathways predicted to be affected by the diversity in miRNA expression after treatment with PIs paves the way for the recognition of new regulatory axes in BrCa.PMID:38038871 | DOI:10.1007/s12094-023-03349-5 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 1, 2023 Category: Cancer & Oncology Authors: Katerina Katsaraki Christos K Kontos Gerasimos Ardavanis-Loukeris Alexandros A Tzovaras Diamantis C Sideris Andreas Scorilas Source Type: research
Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression
by Shota Moriya, Hiromi Kazama, Hirotsugu Hino, Naoharu Takano, Masaki Hiramoto, Shin Aizawa, Keisuke Miyazawa
We previously reported that macrolide antibiotics, such as clarithromycin (CAM), blocked autophagy flux, and simultaneous proteasome and autophagy inhibition by bortezomib (BTZ) plus CAM resulted in enhanced apoptosis induction in multiple myeloma (MM) cells via increased endoplasmic reticulum (ER ) stress loading. However, in actual therapeutic settings, cell adhesion-mediated drug resistance between bone marrow stromal cells (BMSC) and MM cells has been known to be a barrier to treatment. To investigate whether...
Source: PLoS One - December 1, 2023 Category: Biomedical Science Authors: Shota Moriya Source Type: research
Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors
ConclusionsThe diversity of pathways predicted to be affected by the diversity in miRNA expression after treatment with PIs paves the way for the recognition of new regulatory axes in BrCa. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - December 1, 2023 Category: Cancer & Oncology Source Type: research
EE691 Economic Evaluation and Budget Impact of RVd as Induction Regimen Prior to ASCT in Patients with Newly Diagnosed Multiple Myeloma from the Perspective of the Public Health Sector in Mexico
Compare the costs effectiveness of RVd (lenalidomide, bortezomib and dexamethasone) and D-VTd (daratumumab, bortezomib, thalidomide and dexamethasone) as induction regimen prior to autologous stem cell transplantation (ASCT) and estimate the budget impact associated with the use of RVd in this indication, from the perspective of the public health sector in Mexico. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Romero, V. Mena Source Type: research
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.282788. Online ahead of print.ABSTRACTExamination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations with survival outcomes) among newly diagnosed MM patients of non-Hispanic (NH) Black/African American (AA) and NH White race/ethnicity in the United States. We included patients from the nationwide Flatiron Health electronic health record-derived de-identified database who initiated first line of thera...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Tondre Buck Monique A Hartley-Brown Yvonne A Efebera Carter P Milner Jeffrey A Zonder Paul G Richardson Taylor Salinardi Megan S Rice Source Type: research
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of < em > TP53 < /em > mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724. Online ahead of print.ABSTRACTBetween 2011 and 2012, a phase II trial evaluated the use of the RiBVD (Rituximab, Bendamustine, Velcade and Dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients aged over 65. We have now re-examined the classic prognostic factors, adding an assessment of the mutation status of TP53. Patients (n=74; median age 73 years) were treated with the RiBVD combination. Median Progression Free Survival (mPFS) was 79 months, and median Overall Survival (mOS) was 111 months. TP53 mutation status was availa...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Sylvain Carras Alexia Torroja Anouk Emadali Emilie Montaut Nicolas Daguindau Adrian Tempescul Anne Moreau Emmanuelle Tchernonog Anna Schmitt Roch Houot Caroline Dartigeas Sarah Barbieux Selim Corm Anne Banos Ludovic Fouillet Jehan Dupuis Margaret Macro Jo Source Type: research
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.282788. Online ahead of print.ABSTRACTExamination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations with survival outcomes) among newly diagnosed MM patients of non-Hispanic (NH) Black/African American (AA) and NH White race/ethnicity in the United States. We included patients from the nationwide Flatiron Health electronic health record-derived de-identified database who initiated first line of thera...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Tondre Buck Monique A Hartley-Brown Yvonne A Efebera Carter P Milner Jeffrey A Zonder Paul G Richardson Taylor Salinardi Megan S Rice Source Type: research
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of < em > TP53 < /em > mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724. Online ahead of print.ABSTRACTBetween 2011 and 2012, a phase II trial evaluated the use of the RiBVD (Rituximab, Bendamustine, Velcade and Dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients aged over 65. We have now re-examined the classic prognostic factors, adding an assessment of the mutation status of TP53. Patients (n=74; median age 73 years) were treated with the RiBVD combination. Median Progression Free Survival (mPFS) was 79 months, and median Overall Survival (mOS) was 111 months. TP53 mutation status was availa...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Sylvain Carras Alexia Torroja Anouk Emadali Emilie Montaut Nicolas Daguindau Adrian Tempescul Anne Moreau Emmanuelle Tchernonog Anna Schmitt Roch Houot Caroline Dartigeas Sarah Barbieux Selim Corm Anne Banos Ludovic Fouillet Jehan Dupuis Margaret Macro Jo Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research
